FCM MM Holdings Condemns ISS Report on Mind Medicine (MNMD)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
ISS Appears to Rely on MindMed's False and Misleading Statements to Justify the Company's Abysmal Performance; Seemingly Ignores MindMed's Apparent Disregard of Patient Safety
June 5, 2023 6:19 AM EDTISS Dismissed 47% Stock Price Drop Following September 2022 Financing as In Line with Sectoral Trends, in a Baffling Lack of Critical Analysis and Seemingly in Opposition to the Factual Circumstances
After Recommending Removal of Chair Vallone in 2022, ISS Appears to Blindly Accept Vallones and MindMeds Justifications for Poor Development Decisions, Destructive Financing, and Bloated Compensation
ISS Report Reiterates MindMeds False Statements About General and Administrative Costs; Ignores FCMs Explicit Refutation
Flawed and Superficial ISS Analysis of MindMeds Clinical Strategy Leans Heavily on... More
